Bausch & Lomb (TSX:BLCO) Stock Based Compensation : C$100 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Stock Based Compensation?

Bausch & Lomb's Stock Based Compensation for the three months ended in Dec. 2023 was C$21 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was C$100 Mil.

Bausch & Lomb Stock Based Compensation Historical Data

The historical data trend for Bausch & Lomb's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Stock Based Compensation Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

65.85

64.05

79.36

84.23

99.28

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Stock Based Compensation	Get a 7-Day Free Trial											23.09	32.84	23.92	21.65	21.47

Bausch & Lomb Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$100 Mil.

Bausch & Lomb Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.